Endometriosis, defined by the presence of viable endometrial tissue outside the uterine cavity, is a common condition affecting 2–3% of women of reproductive age. Today, a composite theory of retrograde menstruation with implantation of endometrial fragments in conjunction with peritoneal factors to stimulate cell growth is the most widely accepted explanation. There is substantial evidence that immunological factors and angiogenesis play a decisive role in the pathogenesis of endometriosis. In women with endometriosis, there appears to be an alteration in the function of peritoneal macrophages, natural killer cells and lymphocytes. Furthermore, growth factors and inflammatory mediators in the peritoneal fluid, produced mainly by peritoneal macrophages, are altered in endometriosis, indicating a role for these immune cells and mediators in the pathogenesis of this disease.

Endometriosis, pathologically defined by the presence of viable endometrial tissue outside the uterine cavity, is one of the most enigmatic and problematic maladies affecting women of reproductive age. It is associated with pain and infertility and although it is not a malignant disorder, endometriosis exhibits cellular proliferation, cellular invasion and neoangiogenesis. Endometriosis is most commonly implanted over visceral and peritoneal surfaces within the female pelvis. Despite being one of the most frequently encountered gynaecological diseases, the pathophysiology of this disease remains controversial.

The local environment that surrounds the endometriotic implant in the peritoneal cavity is a dynamic one. Histologically, the peritoneum consists of a thin layer of loose connective tissue covered by a layer of mesothelium and is the most extensive serous membrane in the body, with a rich supply of subperitoneal blood vessels and lymphatics.

Retrograde menstruation, peritoneal adhesion of endometrial tissue and outgrowth of these endometrial cells, glands and stroma are essential elements in the pathogenesis of endometriosis, according to Sampson's classical implantation theory. Histologically, the reflux implantation theory of Sampson (1940) was supported by the distribution of the lesions in the abdominal cavity (Jenkins et al., 1986), the demonstration of the viability of shed menstrual endometrium in tissue culture (Keettel and Stein, 1951), the high prevalence of pelvic endometriosis in girls with congenital menstrual outflow obstruction (Sanfilippo et al., 1986) and animal experiments in which endometriosis was induced by the creation of utero–pelvic fistulas (TeLinde and Scott, 1950).

Retrograde menstruation is a universal phenomenon with viable endometrial cells found in peritoneal fluid of 76–90% of women, a prevalence much higher than that of endometriosis (Bartosik et al., 1986). This finding indicates that other factors, such as the amount of retrograde flow or immunological changes, may determine the susceptibility of a woman to endometriosis.

Nevertheless, the stimuli necessary to provide attachment and outgrowth of endometrial cells after arrival in the peritoneal cavity are unknown. This article will review the current understanding of the peritoneal environment in patients with endometriosis as well as its potential role in the development of the disease and its associated pathologies.

Peritoneal fluid in endometriosis

The peritoneal cavity is normally empty except for a thin film of fluid that keeps surfaces moist. The peritoneal fluid arises primarily from two sources: plasma transudate and ovarian exudate. Other sources of peritoneal fluid are tubal fluid, retrograde menstruation and macrophage secretions (Oral et al., 1996).

Studies in women with endometriosis have demonstrated that, in addition to changes in its volume, there are functional changes in several immunological components of the peritoneal fluid, for example phagocytic macrophages–monocytes, natural killer (NK) cells, cytotoxic T lymphocytes, B cells, or inflammatory mediators such as complements and cytokines (Ho et al., 1997a). However, it must be emphasized that the presence of immune cells, cytokines and growth factors does not prove their role in the development or maintenance of endometriosis.
Peritoneal fluid volume

The volume of peritoneal fluid is usually 5–20 ml, and varies widely depending on physiological condition (Oral et al., 1996). For example, peritoneal fluid volume is influenced by the stage of the menstrual cycle, increasing from an early proliferative mean value of 0.8 ml to a mean value of 18.7 ml after ovulation and decreasing again to a mean value of 5.4 ml in the late secretory phase (Bouckaert et al., 1986). This variation may be an indication of an oestrogenic effect on the permeability of vascular and peritoneal membranes (Maathuis et al., 1978).

Conflicting results have been reported on the influence of endometriosis on peritoneal fluid volume. Endometriosis may cause an increase in the fluid production by altering mesothelial permeability or increasing colloid osmotic pressure as a result of altered protein content (Oral et al., 1996). Overall, findings indicate that the volume of peritoneal fluid in women with endometriosis may be modestly increased, but this appears to be of little clinical importance.

Cellular constituents of peritoneal fluid

Peritoneal fluid contains a variety of free-floating cells, including macrophages, NK cells, lymphocytes, eosinophils, mesothelial cells and mast cells.

Macrophages

Macrophages are most abundant type of cell in the peritoneal fluid, and may have a role in the pathogenesis of endometriosis (Ho et al., 1997a). Normally, peritoneal fluid contains $0.5 - 2.0 \times 10^6$ leukocytes ml$^{-1}$, of which 85% are macrophages (Van Furth et al., 1979). The concentration of macrophages appears to fluctuate during the menstrual cycle, and is highest during menses (Oral et al., 1996).

As well as increasing in number, peritoneal macrophages are more activated in endometriosis (Oral et al., 1996). Once activated, macrophages may release products such as cytokines, prostaglandins (PGs), complement components and hydrolytic enzymes, regulating events in the peritoneal cavity. Macrophages can remove red blood cells, damaged tissue fragments and, probably, endometrial cells that gain access to the peritoneal cavity. Endometriosis may develop when the ‘disposal system’ is overwhelmed by high amounts of retrograde menstruation or when a defective peritoneal ‘disposal system’ permits implantation and growth of the endometrial cells or fragments (Dmowski, 1995).

The higher number and activation of macrophages in the peritoneal cavity is also likely to be accompanied by an increase in macrophage-derived cytokines. Some of these cytokines may stimulate the proliferation and differentiation of T cells and, subsequently, T-cell-derived factors may play a critical role in the activation of B cells (Dmowski, 1995). Moreover, it is possible that these cytokines affect other cells present in the peritoneal cavity, such as ectopic endometrial cells.

Available data indicate that products from peritoneal fluid macrophages play an active role in the initiation, maintenance and progression of endometriosis (Senturk and Arici, 1999). Macrophages can induce proliferation of cells, such as fibroblasts and endothelial cells, that are involved in inflammation, tissue repair and neovascularization through secretion of factors such as interleukins, tumour necrosis factor α (TNF-α), macrophage-derived growth factor (MDGF) and monocyte chemotactic protein 1 (MCP-1) (Oral et al., 1996), as well as vascular endothelial growth factor (VEGF) (McLaren, 2000).

Natural killer cells

A defect in NK cell activity in women with endometriosis resulting in a decreased cytotoxicity to autologous endometrium was reported by Oosterlynck et al. (1991). NK cell activity is decreased in the peripheral blood as well as in the peritoneal fluid of women with endometriosis, and this decrease was significantly related to an increase in disease stage (Oosterlynck et al., 1992). Ho et al. (1995) reported that in the peritoneal fluid of women with stage III–IV endometriosis, NK cytotoxicity was significantly lower than it was in women without endometriosis.

These findings have given rise to the NK cell theory of endometriosis, which presupposes that endometriotic cells are natural NK target cells, and that impaired clearance of ectopic endometrium by NK cells in the peritoneal cavity contributes to the development of the disease. However, it can still be argued that alterations in NK cell activity associated with endometriosis can be an effect of the disease. Aberrant NK cell activity may be the result of an imbalance in the immune response to a chronic antigenic stimulus, such as ectopic endometrium, or to a previously initiated autoimmune event unrelated to endometriosis (Hill, 1992). Kikuchi et al. (1993) suggested that changes in the differentiation of NK cells were the consequence of the presence of endometriotic implants.

Studies in which human endometrial tissue has been xenotransplanted into immunodeficient mice demonstrated the importance of NK cells in vivo for the growth of endometrial tissue on ectopic sites. Indeed, nude mice, which have a congenital defect of T and B cells, temporarily accept human endometrial grafts. The same nude mice, when treated with NK anticytotoxic serum before xenotransplantation, permanently accept endometrial grafts. Mice deficient in T and B cells do not reject endometrial grafts (Aoki et al., 1994), indicating an important role for NK cells in the pathogenesis of endometriosis.

Lymphocytes

Approximately 30–50% of peritoneal fluid cells are lymphocytes (Oosterlynck et al., 1992) and their total number is higher in women with endometriosis (Badawy et al., 1984).

Because the T-cell-mediated immune system is involved in the rejection of homologous transplants (Bach and Sachs, 1987), some unique alteration in T-cell function with regard
to rejection has long been considered in women with endometriosis. Evidence to date indicates that changes in cell-mediated immunity occur in women with endometriosis (Ho et al., 1997a). An increased T helper (Th) to T suppressor (Ts) cluster determinant-4 (CD4):CD8 ratio has been noted in peritoneal fluid samples of women with endometriosis, indicating an increased cellular immune activity in the peritoneal environment of these women (Hill et al., 1988). However, Ho et al. (1995) reported that there was no specific change of CD4:CD8 in peripheral blood or in peritoneal fluid in women with endometriosis. Significantly higher numbers of T cells and NK cells, but fewer B lymphocytes and no plasma cells have been observed in the peritoneal fluid of women with endometriosis compared with those in women without the disease (Dmowski et al., 1994).

It is puzzling that T cells have specific cytotoxicity toward autologous endometrial cells to which they are exposed regularly during menstruation. When ectopic endometrial cells implant in the peritoneal cavity, they are processed by activated macrophages and presented to T cells. In women with endometriosis, altered macrophages stimulate implantation and proliferation of misplaced, and possibly altered, endometrial cells (Dmowski et al., 1994). Under the influence of macrophage-released cytokines, the different T-cell subsets (Th1 and Th2) can proliferate and differentiate into functionally activated cells. After T-cell activation, two different groups of cytokines, Th1 and Th2 cytokines, are secreted from corresponding cells. Th1 cytokines, including interleukin 2 (IL-2), IL-12, interferon γ, as well as TNF-α and TNF-β, generally result in cellular immunity, whereas Th2 cytokines, IL-4, IL-5, IL-6, IL-10 and IL-13, activate B cells, resulting in their differentiation and proliferation into antibody-secreting plasma cells. Preliminary studies using RT–PCR demonstrated that the peritoneal T cells of women with endometriosis express predominant Th1 cytokine, IL-2 and interferon γmRNA (Ho et al., 1997b).

Peritoneal fluid soluble constituents

Steroid hormones

The influence of hormones on the development of endometriosis was postulated by Novak (1931). The probability of hormonal modulation of endometriosis is supported by the presence of oestrogen and progesterone receptors in endometriotic lesions (Bergqvist et al., 1993). A distinction should be made between the influence of hormones in initiating and in maintaining endometriosis. The initiation of growth of endometriosis in monkeys has been shown to be independent of oestrogens; however, either oestradiol or progesterone, alone or in combination, is required for maintenance of the long-term viability of endometriotic implants (DiZerega et al., 1980). These studies of the influence of oestrogens and progesterone were performed in an animal model with surgically implanted endometrium.

In spontaneous endometriosis, cyclic ovarian hormone secretion seems necessary for the growth or proliferation of ectopic endometrial tissue. However, the exact mechanisms underlying the differentiation in the proliferation of endometrial deposits are not clear. It is conceivable that the mitogenic effect of oestrogen is modulated by locally produced paracrine and autocrine factors (Tabibzadeh et al., 1988). However, there appears to be no significant difference in the concentrations of oestradiol or progesterone in peritoneal fluid between women with endometriosis and controls free of the disease (Mahmood and Templeton, 1991).

Prostaglandins

Prostaglandins are biosynthesized from polyunsaturated fatty acids (PUFAs), predominantly arachidonic acid. Sources of prostaglandins in peritoneal fluid are the peritoneal macrophages, the peritoneal surface, ovarian follicles and endometriotic implants (Ylikorkala and Viinikka, 1983). In addition, passive diffusion occurs from other organs in the peritoneal cavity.

Prostaglandins may be involved in the pathogenesis of endometriosis (Bulun et al., 2000). Peritoneal macrophages from women with endometriosis release significantly more PGE₂ and PGF₂α compared with macrophages from women without endometriosis (Karck et al., 1996). Prostaglandins, which play a prominent role in the physiology of endometrium, are also involved in the regulation of the production and function of cytokines (Graham et al., 1994). PGE₂ is thought to be a potent inducer of aromatase activity in endometriotic stromal cells (Noble et al., 1997; Bulun et al., 2000). Aromatase activity gives rise to local biosynthesis of oestrogen, which in turn stimulates PGE₂ production, thus establishing a positive feedback cycle. The tissue localization of the prostaglandin receptor family in the context of endometriotic tissue remains unclear, but there is evidence that prostaglandin concentrations are increased in the peritoneal fluid of women with endometriosis, indicating their possible importance in the aetiology of the disease.

Cytokines and growth factors

As discussed above, macrophages in the peritoneal cavity release cytokines and growth factors in response to a variety of inflammatory stimuli. Cytokine activities are varied and include the following: proliferation and differentiation of immune cells; induction of release of hormones, enzymes and acute phase proteins; enhancement of various cytotoxic activities; regulation of immunoglobulin secretion; and chemotaxis. In general, cytokines exert biological effects on a variety of cell types (that is, they are pleiotropic) but, in addition, they may either induce or downregulate the production of other cytokines.

Interleukin 1. High concentrations of IL-1 have been found in the peritoneal fluid of women with endometriosis (Ho et al., 1997a). In culture, macrophages from the peritoneal fluid of endometriosis patients produce more IL-1.
than do those of controls (Mori et al., 1991). There are several physiological and pathological effects attributed to IL-1 that may relate to endometriosis. IL-1 induces the synthesis of prostaglandins, and stimulates fibroblast proliferation, collagen deposition and fibrinogen formation, which could contribute to the fibrosis and adhesion formation associated with endometriosis. In addition, IL-1 stimulates B-cell proliferation and antibody production, which could be related to the autoantibodies associated with the disease (Senturk and Arici, 1999). IL-1 also stimulates IL-2 secretion by T cells and NK cells, which in turn can induce NK proliferation and T-cell growth (Dilloo et al., 1994).

**Interleukin 6.** IL-6 is a potent cytokine that has diverse effects, several of which are potentially related to tissue repair, including stimulation of angiogenesis (Le and Vilcek, 1989). IL-6 may be secreted by macrophages in response to a variety of substances found in the peritoneal fluid, including IL-1 (Sironi et al., 1989). IL-6 is an activator of macrophages (Akira et al., 1993) and promotes cellular proliferation of endometrium (Giudice, 1994). Endometriotic stromal cells express IL-6 mRNA and produce IL-6 protein (Tsudo et al., 2000). In addition, increased concentrations of IL-6 have been noted in the ectopic endometrial tissue culture (Keenan et al., 1994), peripheral blood (Koumantakis et al., 1994) and peritoneal fluid of women with endometriosis (Punnonen et al., 1996).

In contrast, the study of Buyalos et al. (1992) failed to show a difference in peritoneal fluid IL-6 concentrations between normal women and women with endometriosis. Rapkin et al. (2000) also found no significant differences in the peritoneal fluid IL-6 concentrations between women with and without endometriosis, whereas Mahnke et al. (2000) reported significantly higher concentrations of IL-6 in the peritoneal fluid of women with more extensive disease. Taken together, the available evidence indicates that IL-6 may be involved in the pathogenesis of endometriosis. However, further research is needed to clarify its exact role in the disease process.

**Interleukin 8.** IL-8 is a potent angiogenic, proinflammatory, growth-promoting cytokine (Koch et al., 1992). It is a chemoattractant for neutrophils and induces the expression of several cell adhesion molecules (Koch et al., 1992). It can also lead to neutrophil activation (Peveri et al., 1989) and hence may contribute to the pathogenesis of inflammatory diseases such as endometriosis. The presence of inflammation and neovascularization observed in and around ectopic endometrial implants, and the presence of inflammatory neutrophils in these lesions is compatible with the biological actions of IL-8 (Van Deuren et al., 1992).

Rana et al. (1996) reported increased concentrations of IL-8 in the peritoneal fluid from women with endometriosis, of which a substantial amount was suggested to be derived from peritoneal macrophages. It has also been suggested that IL-8 stimulates the growth of ectopic (Harada et al., 1999) as well as eutopic endometrial cells and DNA synthesis in a dose-dependent manner (Iwabe et al., 1998). In addition, endometrium produces IL-8 (Arici et al., 1998a), which, in turn, induces the proliferation of endometrial stromal cells (Arici et al., 1998b). This finding may be important since it is possible that excessive endometrial angiogenesis plays a role in the pathogenesis of endometriosis. It appears that IL-8 is involved in the pathogenesis of endometriosis. What is not clear is whether IL-8 is an initiating factor or a consequence of the presence of endometriotic explants within the peritoneal environment.

**Interleukin 10.** Significantly higher concentrations of IL-10 are found in women showing early stages of endometriosis compared with normal women (Ho et al., 1997b). IL-10 is also found at higher concentrations in the peritoneal fluid, which may be a result of enhanced macrophage activity in women with endometriosis (Punnonen et al., 1996). High concentrations of both IL-6 and IL-10 may contribute to the disturbed immune regulation observed in women with endometriosis. Punnonen et al. (1996) also reported that the activated peritoneal CD4+ Th1 cells from women with endometriosis were decreased in number and suggested that the suppression of T cells is the result of the increased IL-10 in the peritoneal fluid.

However, in a conflicting study (McLaren et al., 1997), no differences with respect to IL-10 concentrations were observed in the peritoneal fluid of women with or without endometriosis. In agreement with the findings of Punnonen et al. (1996), Wu et al. (1999) reported increased production of IL-10 and IL-6 by the peritoneal macrophages from women with endometriosis, confirming observations that the peritoneal macrophages are the principal source of these cytokines in peritoneal fluid. Given that both IL-10 and IL-6 are potent modulators of inflammatory responses, B-cell and macrophage functions in particular, it is likely that increased IL-10 and IL-6 production is responsible, in part, for the disturbed immune regulation observed in patients with endometriosis.

**Interleukin 13.** IL-13 is a macrophage-inhibiting cytokine. McLaren et al. (1997) reported that women with endometriosis had significantly lower concentrations of IL-13 in peritoneal fluid, compared with women without endometriosis. Immunolocalization of IL-13 indicates that glandular epithelial cells and stromal cells in both eutopic and ectopic endometrium are immunopositive for IL-13. Therefore, the reduced amounts of IL-13 in the peritoneal fluid of women with endometriosis may lead to a lack of suppression of macrophage activation, thereby contributing to the overall pathogenesis of the disease. Further work is needed to confirm these findings and clarify the role of IL-13 in the pathogenesis of endometriosis.

**Tumour necrosis factor α.** The concentration of TNF-α, a cytokine with a wide range of biological effects, is also increased in the peritoneal fluid of women with endometriosis (Richter et al., 1998) and its concentrations may correlate with the stage of the disease (Richter et al., 1998). TNF-α is made by a wide variety of cells, including...
fibroblasts, macrophages and T and B cells, and has a biphasic effect on the growth of human endometrial adenocarcinoma cells in vitro (Inniss et al., 1992). TNF-α also enhances the adhesion of endometrial stromal cells to mesothelial cells when included in the culture medium (Zhang et al., 1993). The results of a study carried out in a rat model of endometriosis support the role of TNF in the development of endometriosis and provide evidence of the potential effectiveness of recombinant human TNF binding protein 1 (rhTBP-1) in its treatment (D’Antonio et al., 2000). Iwabe et al. (2000) demonstrated that TNF-α stimulates proliferation of endometriotic stromal cells through induction of IL-8 gene and protein expression and concluded that the TNF-α may be one of the essential factors for the pathogenesis of endometriosis.

Intercellular adhesion molecule 1. Intercellular adhesion molecule 1 (ICAM-1) is a soluble molecule that can interfere with immunological functions, and may play important roles in the initiation and regulation of endometriotic lesions. ICAM-1-mediated cell–cell adhesion is essential for various immunological functions, including NK cell-mediated cytotoxicity against endometrium. In patients with endometriosis, concentrations of soluble ICAM-1 in peritoneal fluid are increased and this interferes with the activity of NK cells. This finding implies that the increased ICAM-1 impairs NK cell activity and accelerates the progression of the disease (Konincx et al., 1998). Endometriotic cells may show significant over-expression of ICAM-1 protein compared with eutopic endometrium (Vigano et al., 1998). Therefore, the release of higher concentrations from ectopic samples may be the mechanism by which ectopic endometrial cells escape immunosurveillance (Somigliana et al., 1996). Significantly high concentrations of soluble ICAM-1 have also been found in the sera of patients with endometriosis, especially those with advanced stages of the disease (Wu et al., 1998). Available data on ICAM-1 is in agreement with the contention that this cytokine plays a role in the pathophysiology of endometriosis.

Monocyte chemotactic protein 1. Peritoneal fluid from patients with endometriosis has increased chemotactic activity for macrophages (Leiva et al., 1993). MCP-1 is a potent chemotactic and activating factor specific for monocytes (Oral et al., 1996). MCP-1 is secreted by a number of cell types, including endothelial cells, fibroblasts (Yoshimura and Leonard, 1990) and leukocytes (Yoshimura et al., 1989). Concentrations of MCP-1 are high in the peritoneal fluid of women with endometriosis (Arici et al., 1997), and are correlated with the severity of the disease. However, in women who have undergone medical treatment with gonadotrophins, the concentrations of MCP-1 are suppressed (Arici et al., 1997).

Human endometrial tissue expresses MCP-1 and this expression is regulated by IL-1, TNF-α, platelet-derived growth factor (PDGF), and interferon γ in endometrial cell culture (Arici et al., 1995). Secretion of MCP-1 is upregulated in cytokine-stimulated endometrial cells of women with endometriosis but not in those of normal women (Akoum et al., 1995).

Increased concentrations of MCP-1 may play a role in the growth and maintenance of ectopic endometrial tissue by not only stimulating macrophages to secrete growth factors and cytokines, but also by stimulating endometrial cell proliferation directly (Arici et al., 1997). Whether the increased MCP-1 in peritoneal fluid is a cause or consequence of the disease is not known. Taken together, these findings make it plausible that MCP-1 is involved in the pathogenesis of endometriosis and support the contention that pathophysiological changes are present in the eutopic endometrium of patients with endometriosis.

RANTES. RANTES (regulated upon activation, normal T cell expressed and secreted) is a cytokine with monocyte, macrophage, T-lymphocyte, and eosinophil attractant and activating properties discovered in the early 1990s (Schall et al., 1990). The peritoneal fluid concentrations of RANTES are increased in women with endometriosis and concentrations are related to the severity of the disease (Khorram et al., 1993). The exact role of this cytokine in the pathophysiology of endometriosis is not yet clearly understood.

Vascular endothelial growth factor. VEGF is a potent angiogenic factor involved in both physiological and pathological angiogenesis. Sources of VEGF include the eutopic endometrium, ectopic endometriotic tissue and peritoneal fluid macrophages. There is increasing evidence to indicate that the VEGF family is involved with both the aetiology and maintenance of peritoneal endometriosis (McLaren, 2000). Peritoneal fluid from patients with endometriosis contains significantly greater amounts of VEGF than controls, and there are increased VEGF concentrations in peritoneal fluid from women with more advanced endometriosis (Mahnke et al., 2000). These findings indicate that the inflammation associated with endometriosis may promote angiogenesis for the progressive growth of the disease through increased VEGF concentrations (McLaren, 2000). Treatment of women with endometriosis with a GnRH agonist resulted in significant decreases in mean peritoneal fluid VEGF concentrations (Kupker et al., 1998), indicating a role for VEGF in the establishment and maintenance of endometriosis.

Insulin-like growth factor. Insulin-like growth factor (IGF) is another well-known mitogenic peptide, and has a possible role as one of several mediators of oestrogen and other growth factors in various body tissues (Yap et al., 1998). IGF-I concentrations in peritoneal fluid are significantly higher (Kim et al., 2000) and IGF-binding protein-3 (IGFBP-3) concentrations and the relative proportion of IGFBP-2 are significantly lower, in patients with endometriosis than they are in women without endometriosis, indicating the involvement of the IGF system in the pathophysiology of endometriosis. The IGF peptides and their receptors have also been demonstrated...
Table 1. Peritoneal factors suggested to be related to endometriosis

<table>
<thead>
<tr>
<th>Peritoneal factor</th>
<th>Activity</th>
<th>Origin of evidence</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Steroid hormones</td>
<td>Maintenance of endometriosis</td>
<td>In vitro, animal and human</td>
<td>DiZerega et al., 1980; Mahmood and Templeton, 1991; Bergqvist et al., 1993</td>
</tr>
<tr>
<td>Prostaglandins</td>
<td>Induce aromatase, modulate cytokine production and function</td>
<td>In vitro and animal</td>
<td>Graham et al., 1994; Bulun et al., 2000</td>
</tr>
<tr>
<td>IL-1</td>
<td>Induce prostaglandin synthesis, collagen deposition, stimulate IL-2 and IL-6 as well as autoantibody production</td>
<td>In vitro</td>
<td>Dilloo et al., 1994; Senturk and Arici, 1999</td>
</tr>
<tr>
<td>IL-6</td>
<td>Stimulate angiogenesis, promote cellular proliferation</td>
<td>In vitro</td>
<td>Le and Vilcek, 1989; Giudice et al., 1994</td>
</tr>
<tr>
<td>IL-8</td>
<td>Stimulate angiogenesis, inflammation and cell proliferation</td>
<td>In vitro, animal and human</td>
<td>Koch et al., 1992; Van Deuren et al., 1992; Rana et al., 1996; Arici et al., 1998a,b</td>
</tr>
<tr>
<td>IL-10</td>
<td>Modulate inflammatory response</td>
<td>In vitro</td>
<td>Punnonen et al., 1996; Wu et al., 1999</td>
</tr>
<tr>
<td>IL-13</td>
<td>Inhibit macrophages</td>
<td>In vitro</td>
<td>McLaren et al., 1997</td>
</tr>
<tr>
<td>TNF-α</td>
<td>Stimulate cell proliferation and adhesion</td>
<td>In vitro and animal</td>
<td>Ininns et al., 1992; Zhang et al., 1993; D’Antonio et al., 2000; Iwabe et al., 2000</td>
</tr>
<tr>
<td>ICAM-1</td>
<td>Mediate cell adhesion, impair natural killer cell activity</td>
<td>In vitro</td>
<td>Somigliana et al., 1996; Konincks et al., 1998</td>
</tr>
<tr>
<td>MCP-1</td>
<td>Activate macrophages, stimulate cell proliferation and maintain ectopic endometrium</td>
<td>In vitro</td>
<td>Oral et al., 1996; Arici et al., 1997</td>
</tr>
<tr>
<td>RANTES</td>
<td>Attract cytokine, macrophage and T lymphocytes</td>
<td>In vitro</td>
<td>Schall et al., 1990</td>
</tr>
<tr>
<td>VEGF</td>
<td>Stimulate angiogenesis</td>
<td>In vitro, animal and human</td>
<td>Kupker et al., 1998; McLaren, 2000; Mahnke et al., 2000</td>
</tr>
<tr>
<td>IGF</td>
<td>Stimulate mitosis, mediate oestrogen and other growth factors</td>
<td>In vitro</td>
<td>Giudice et al., 1994; Yap et al., 1998</td>
</tr>
<tr>
<td>PDGF</td>
<td>Potentiate mitosis</td>
<td>In vitro</td>
<td>Surrey and Halme, 1991; Chegini et al., 1992</td>
</tr>
<tr>
<td>EGF</td>
<td>Stimulate mitosis, mediate oestrogen action</td>
<td>In vitro</td>
<td>Chegini et al., 1992; Mellor and Thomas, 1994</td>
</tr>
<tr>
<td>bFGF</td>
<td>Induce angiogenesis and mitosis</td>
<td>In vitro, animal</td>
<td>Folkman and Klagsbrun, 1987; Irwin et al., 1991</td>
</tr>
<tr>
<td>M-CSF</td>
<td>Stimulate proliferation and growth</td>
<td>In vitro</td>
<td>Weinberg et al., 1991; Stanley et al., 1997</td>
</tr>
<tr>
<td>TGF-β</td>
<td>Induce angiogenesis, chemoattrac monocytes, inhibit natural killer cell, T and B lymphocyte function</td>
<td>In vitro</td>
<td>Rook et al., 1986; Oral et al., 1996</td>
</tr>
<tr>
<td><em>In vitro</em></td>
<td>Stimulate proliferation and mitosis</td>
<td>In vitro</td>
<td>Fukaya et al., 1999; Laping, 1999</td>
</tr>
</tbody>
</table>

bFGF: basic fibroblast growth factor; EGF: epidermal growth factor; ICAM-1: intercellular adhesion molecule 1; IGF: insulin-like growth factor; IL: interleukin; M-CSF: macrophage-colony stimulating factor; MCP-1: monocyte chemotactic protein 1; RANTES: regulated upon activation, normal T cell expressed and secreted; TGF-β: transforming growth factor β; TNF-α: tumour necrosis factor α; VEGF: Vascular endothelial growth factor.
immunohistochemically in ectopic endometrial tissues (Chang and Ho, 1997). In addition, IGFs are mitogenic to endometrial stromal cells cultured in vitro (Giudice et al., 1994), indicating a role for this group of peptides in the pathogenesis of endometriosis.

**Platelet-derived growth factor.** PDGF is a well-characterized secretory product of activated macrophages and plays a major role in the inflammatory response as a potent mitogen for fibroblasts and angiogenic precursor cells as well as endometrial cells (Chegini et al., 1992). PDGF has been identified in the peritoneal fluid of women with endometriosis (Halme et al., 1988) and has a significant dose-dependent proliferative effect on endometrial stromal and epithelial cells (Surrey and Halme, 1991). Further work is needed to clarify the exact role of PDGF in endometriosis.

**Epidermal growth factor.** Epidermal growth factor (EGF) is mitogenic for human endometrial cells (Chegini et al., 1992). EGF concentrations in the peritoneal fluid are high in women with endometriosis (Simms et al., 1991). EGF concentrations are also positively correlated with the day of the cycle, and are highest during the luteal phase (DeLeon et al., 1986).

Oestrogen action in the endometrium may be mediated by the peptide growth factors, in particular EGF (Mellor and Thomas, 1994). EGF exerts its effects through binding to its cell surface receptor, which is expressed in the glands and stroma of eutopic and ectopic endometrium of women with endometriosis (Prentice et al., 1992). However, in a somewhat conflicting report, Huang et al. (1996) have suggested that there is no difference in the peritoneal fluid concentrations of EGF between women with and without endometriosis. The role of EGF in the pathogenesis of endometriosis remains unclear.

**Basic fibroblast growth factor.** Basic fibroblast growth factor (bFGF) is a heparin-binding angiogenic protein that is highly mitogenic for capillary endothelial cells in vitro and can induce angiogenesis in vivo (Folkman and Klagsbrun, 1987). Secretion of bFGF by endometrial cells increases in response to oestradiol and is inhibited by progesterone (Presta, 1988). bFGF is present in endometrial glandular epithelium and is a potent mitogen for endometrial stromal cells in culture (Irwin et al., 1991). Peritoneal fluid concentrations of bFGF do not differ significantly between women with and without endometriosis (Seli et al., 1998). Although findings in vitro indicate that bFGF may be involved in endometriosis, there is as yet insufficient evidence to support this theory.

**Macrophage-colony stimulating factor.** Peritoneal fluid concentrations of the growth factor, macrophage-colony stimulating factor (M-CSF), correlate with the total number of macrophages (Weinberg et al., 1991). M-CSF has been identified at significantly higher concentrations in the peritoneal fluid of women with endometriosis (Weinberg et al., 1991) and is involved in the differentiation of monocytes to become phenotypically activated macrophages in addition to serving as a chemotactic factor for blood monocytes. M-CSF may regulate the proliferation of endometrial tissue (Stanley et al., 1997) and hence have a role in the development of endometriosis.

**Transforming growth factor β.** In addition to its growth regulating properties, transforming growth factor-β (TGF-β) is one of the most potent chemoattractants for human monocytes and is an inducer of fibrosis and angiogenesis (Ooral et al., 1996). Furthermore, TGF-β has striking immunological effects and can profoundly inhibit T-lymphocyte, B-lymphocyte and NK cell functions (Rook et al., 1986). The peritoneal fluid of women with endometriosis contains increased TGF-β activity, and Oosterlynck et al. (1994) suggested that the decreased NK activity of peritoneal fluid in women with endometriosis is secondary to increased TGF-β activity. Women with stage III and IV endometriosis have higher concentrations of TGF-β compared with women with milder endometriosis, and a significant decrease in concentrations was achieved after treatment with a GnRH agonist (Kupker et al., 1998), indicating a role for paracrine activity in endometriosis.

**Hepatocyte growth factor.** Hepatocyte growth factor (HGF) is an injury-released growth factor with diverse effects on epithelial and endothelial cells. These effects include proliferation, migration, extracellular matrix production and tubulogenesis (Laping, 1999). HGF concentrations in the peritoneal fluid of women with stage III–IV endometriosis are significantly higher than those from women without endometriosis. The concentrations from women with stage I–II endometriosis appear to be intermediate (Osuga et al., 1999). HGF secretion is significantly increased in cultured endometrial stromal cells (Fukaya et al., 1999), and HGF stimulates the proliferation and migration of, and morphogenic changes in, endometrial epithelial cells (Fukaya et al., 1999). Given the known mitogenic properties of HGF, its increased secretion by eutopic endometrial stromal cells and higher peritoneal fluid concentrations in advanced endometriosis imply that it may play a role in the progression of endometriosis.

**Conclusions**

Discrepancies among studies about the changes in peritoneal immunology in women with endometriosis remain as a result of differences in the methodologies used and in the severity of endometriosis studied. However, in general, it is agreed that a local, sterile inflammation occurs in the peritoneal cavity and there is substantial evidence that immunological factors and angiogenesis play a decisive role in the pathogenesis of the disease. The reported data on various peritoneal factors included in this review are summarized (Table 1).

---

**Table 1.** Various peritoneal factors included in this review are summarized.
Peritoneal macrophages play a pivotal role in the intra-abdominal environment. They increase in number and are activated in women with endometriosis. Endometrial tissue, after arrival in the peritoneal cavity, is likely to adhere to the mesothelial lining if the regurgitated amount of tissue is too great or if the capacity of the intra-abdominal cells to clear the abdominal cavity is impaired. The adhesion may be mediated by cell adhesion molecules and soluble factors produced by peritoneal macrophages in an advanced stage of differentiation. After adherence, endometrial tissue growth is promoted by steroids, growth factors and angiogenic factors present in the peritoneal fluid, in a paracrine and autocrine fashion.

The development of ectopic endometrium requires an accessible blood supply. The peritoneal fluid of women with endometriosis displays greater angiogenic activity than does fluid obtained from women without the disease (Oosterlynck et al., 1993). Angiogenic and growth stimulating factors in the peritoneal fluid, peritoneum and endometriotic implants of women with endometriosis have been studied extensively. It may be postulated that the release of angiogenic factors into the peritoneal compartment produces an increased microvascularization of the parietal peritoneum. However, it must be emphasized that the mere presence of these cytokines, growth factors and macrophage attractants and the production in vitro of growth-promoting factors by macrophages do not prove their involvement in the development or maintenance of the disease. In addition, the factors discussed were detected in women who had already developed endometriosis, and may therefore have been a consequence rather than a cause of the disease.

Progress made recently in studies of peritoneal fluid regarding the pathogenesis of endometriosis sheds new light on the fundamental quandaries of this mysterious disease. Although cellular and chemical alterations in the peritoneal fluid are apparent, many questions remain to be answered. It is unlikely that immunological changes in isolation will explain the pathophysiology of endometriosis. The effects of various cytokines and growth factors in the peritoneal fluid of endometriosis are complicated, and a clear delineation of the roles of each of these factors is lacking. Much more work is needed in this area to clarify the role of each individual cytokine and growth factor in the pathogenesis of endometriosis.

References

Key references are identified by asterisks.

Akira S, Taga T and Kishimoto T (1993) Interleukin 6 in biology and medicine. Advances in Immunology 54 1–78


Bartsos DJ, Jacobs SL and Kelly LJ (1986) Endometrial tissue in peritoneal fluid Fertility and Sterility 46 796–800


Chegini N, Rossi MJ and Masterson BJ (1992) Platelet-derived growth factor (PDGF), epidermal growth factor (EGF), and EGF and PDGF beta-receptors in human endometrial tissue; localization and in vitro action Endocrinology 130 2373–2385


Giudice LC (1994) Growth factors and growth modulators in human uterine
endometrium: their potential relevance to reproductive medicine
Fertility and Sterility 61 1–11
Graham J, Franks S and Bonney RC (1994) In vivo and in vitro effects of gamma-linolenic acid and eicosapentaenoic acid on prostaglandin production and arachidonic acid uptake by human endometrium
Prostaglandins, Leukotrienes and Essential Fatty Acids 50 321–329
macrophages from patients with endometriosis release growth factor
1044–1049
Karck U, Reister F, Schafer W, Zahradnik HP and Breckwoldt M
(1996) Interleukin 6 and interleukin 10 in women with stage III–IV
endometriosis Human Reproduction 11 2528–2533
Koch AE, Polverini PJ, Kunkel SL, Harlow LA, DiPietro LA, Einer VM, Einer SG,
Strieter RM (1992) Interleukin 8 as a macrophage derived mediator of
angiogenesis Science 258 1798–1801
Koninckx PR, Kennedy SH and Barlow DH (1998) Endometriotic disease:
the role of peritoneal fluid Human Reproduction Update 4 741–751
Koumantakis E, Matalliotakis I, Neonaki M, Froudarakis G and Georgoulas V
(1994) Soluble serum interleukin 2 receptor, interleukin 6 and
interleukin 1a in patients with endometriosis and in controls Archives
of Gynecology and Obstetrics 255 107–112
the peritoneal environment of women with endometriosis Human
Reproduction Update 4 719–723
Laping NJ (1999) Hepatocyte growth factor in renal disease: cause or cure?
Cell and Molecular Life Science 56 371–377
immune reactions and the acute phase protein response Laboratory
Investigation 61 588–602
Increased chemotactic activity of peritoneal fluid in patients with
endometriosis American Journal of Obstetrics and Gynecology 168
592–598
Mathijs JB, Van Look PFA and Michie EA (1978) Changes in volume, total
protein and ovarian steroid concentration of peritoneal fluid throughout
the menstrual cycle Journal of Endocrinology 76 123–133
McLaren J (2000) Vascular endothelial growth factor and endometriotic
angiogenesis Human Reproduction Update 6 45–55
Decreased levels of a potent regulator of monocyte/macrophage
activation, interleukin 13, in the peritoneal fluid of patients with
endometriosis Human Reproduction 12 1307–1310
Mahmood TA and Templeton A (1991) Peritoneal fluid volume and sex
steroids in the pre-ovulatory period in mild endometriosis British Journal
of Obstetrics and Gynaecology 98 179–183
Mahnke JL, Dawood MY and Huang JC (2000) Vascular endothelial growth
factor and interleukin 6 in peritoneal fluid of women with endometriosis
Fertility and Sterility 73 166–170
Mellor SJ and Thomas EJ (1994) The actions of estradiol and epidermal
growth factor in endometrial and endometriotic stroma in vitro. Fertility
and Sterility 62 507–513
Decreased levels of a potent regulator of monocyte/macrophage
activation, interleukin 13, in the peritoneal fluid of patients with
endometriosis Human Reproduction 12 1307–1310
Novak E (1931) Pelvic endometriosis American Journal of Obstetrics and
Gynecology 22 826–837
Oosterlynck DJ, Meuleman C, Sobis H, Vanpeutte M and Koninckx PR
(1991) Women with endometriosis show a defect in natural killer
activity resulting in a decreased cytotoxicity to autologous endometrium
Fertility and Sterility 56 45–51
Oosterlynck DJ, Meuleneire C, Waer M, Vandeputte M and Koninckx PR
(1992) The natural killer activity of peritoneal fluid lymphocytes is
decreased in women with endometriosis Fertility and Sterility 58
290–295
Oosterlynck DJ, Meuleneire C, Sobis H, Vandeputte M and Koninckx PR
(1993) Angiogenic activity of peritoneal fluid from women with
endometriosis Fertility and Sterility 59 778–782
endometriosis Human Reproduction Update 2 385–398

Angiogenesis in endometriosis

growth factors (IGFs), IGF-binding proteins (IGFBPs), and IGFBP-3
protease activity in the peritoneal fluid of patients with and without
endometriosis Fertility and Sterility 73 996–1000


Presta M (1988) Sex hormones modulate the synthesis of basic fibroblast growth factor in human endometrial adenocarcinoma cells: implications for the neovascularization of normal and neoplastic endometrium. Journal of Cell Physiology 137 593–597


